What is new in heart failure with preserved ejection fraction within last five years?

Czech version

Authors: Zdeňka Gregorová ^1,2; Jaroslav Meluzín ^1,2; Lenka Špinarová ^1,2
Authors‘ workplace: I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, Ph. D., FESC ¹; Mezinárodní centrum klinického výzkumu FN u sv. Anny Brno, ředitel Gorazd B. Stonkin, M. D., MSc., Ph. D. ²
Published in: Vnitř Lék 2014; 60(7-8): 586-594
Category: Reviews

Overview

Heart failure with preserved ejection fraction of left ventricle (heart failure with normal ejection fraction, HFPEF, HFNEF) is frequent disease with serious consequences. Incidence of HFPEF in population is still growing. The exact pathophysiological mechanism of HFPEF remain unclear .Recent evidence suggests a relationship between inflammation associated with obesity or Diabetes mellitus and progression of HFPEF. Consistently, it has been reported that serum concentration of some pro-inflammatory markers such as adiponectin is positively related to HFPEF. By HFPEF is attended diastolic dysfunction. Diastolic dysfunction is linked to many other cardiac and non-cardiac diseases. Despite the great effort and new therapeutic approaches the prognosis of HFPEF does not improve. The gold standard in HFPEF diagnosis remains heart catheterization. Electrocardiography, chest X-ray, blood examination including diagnostic markers of heart failure and mainly echocardiography with Doppler imaging are used diagnose the underlying disease leading to heart failure.

Key words:
diastolic dysfunction – heart failure – left ventricle – preserved ejection fraction of left ventricle

Sources

1. Borlaug BA, Walter JP. Heart failure with preserved ejection fraction: patophysiology, diagnosis and treatment. Eur Heart J 2011; 32(6): 670–679.

2. Paulus WJ, Tschope C, Sanderson JE et al. How To Diagnose Diastolic Heart Failure: A Consensus Statement on the Diagnosis of Heart Failure and Echocardiography Associations of The European Society of Cardiology. Eur Heart J 2007; 28(12): 2539–2550.

3. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for The Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiogr 2009; 22(2): 107–133.

4. Hanrath P, Mathey DG, Siegert R et al. Left ventricular Relaxation and Filling Pattern in Different Forms of Left Ventricular Hypertrophy: An Echocardiographic Study. Am J Cardiol 1980; 45(1): 15–23.

5. Hess OM, Grimm J, Krayenbuehl HP. Diastolic simple elastic and viscoelastic properties of the left ventricle in man. Circulation 1979; 59(6): 1178–1187.

6. Soufer R, Wohlgelernter D, Vita NA et al. Intact Systolic Left Ventricular Function in Clinical Congestive Heart Failure. Am J Cardiol 1985; 55(8): 1032–1036.

7. McMurray J, Pfeffer MA. New Therapeutic Options in Congestive Heart Failure: Part II. Circulation 2002; 105(18): 2223–2228.

8. Owan TE, Hodge DO, Herges RM et al. Trends in Prevalence and Outcome of Heart Failure With Preserved Ejection Fraction. N Engl J Med 2006; 355(3): 251–259.

9. Magana-Serrano JA, Almahmeed W, Gomez E et al. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER Study (Identification of Patients With Heart Failure and PREserved Systolic Function: and epidemiological regional study). Am J Cardiol 2011; 108(9): 1289–1296.

10. Russo C, Jin Z, Homma S et al. Race/ethnic Disparities in Left Ventricular Diastolic Function in a Triethnic Community Cohort. Am Heart J 2010; 160(1): 152–158.

11. Kelly RV, Tan WA, Cho H et al. Prevalence of Symptomatic Diastolic Heart Failure in Patients Hospitalized With Cerebral or Peripherial Vascular Disease. Congest Heart Fail 2005; 11(5): 256–261.

12. Zhang Y, Safar ME, Iaria P et al. Prevalence and Prognosis of Left Ventricular Diastolic Dysfunkcion in The Elderly: The PROTEGER Study. Am Heart J 2010; 160(3): 471–478.

13. Kazuhiro Y, Sakata Q, Ohtani T et al. Heart Failure With Preserved Ejection Fraction. What is Known and Unknown. Circ J 2009; 73(3): 404–410.

14. Hradec J. Anémie při chronickém srdečním selhání. Vnitř Lék 2010; 56(8): 854–859.

15. Hsich EM, Grau-Sepulveda V, Hernandez AF et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am Heart J 2012; 163(3): 430–437.

16. Elshaer F, Hassan W, Fawzy ME et al. The prevalence, clinical characteristics, and prognosis of diastolic heart failure: a clinical study in elderly saudi patients with up to 5 years follow-up. Congest Heart Fail 2009; 15(3): 117–122.

17. Aguilar D, Deswal A, Ramasubbu K et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010; 105(3): 373–377.

18. McMurray J, Komajda M, McKelvie R et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008; 10(2): 149–156.

19. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47(1): 76–84.

20. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126(1): 65–75.

21. Selvaraj S, Klein I, Danzi S et al. Association of serum triiodthyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunktion in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110(2): 234–239.

22. Negi SI, Jeong E, Shukrullah I et al. Association of Low Plasma Adiponectin With Early Diastolic Dysfunction. Congest Heart Fail 2012; 18(4): 187–191.

23. Borlaug BA, Olson TP, Lam CSP et al. Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2010; 56: 845–854.

24. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med 2006; 355: 251–259.

25. Yamamoto K, Masuyama T, Sakata Y et al. Role of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000; 47(2): 274–283.

26. Koitabashi N, Arai M, Kogure S et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007; 49(5): 1120–1127.

27. Borbely A, van der Velden J, Papp Z et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111(6): 774–781.

28. Van Heerebeek L, Borbely A, Niessen HWM et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113(16): 1966–1973.

29. Sakata Y, Masuyama T, Yamamoto K et al. Calcineurin inhibitor attenuates left ventricular hypertrophy leading to prevention of heart failure in hypertensive rats. Circulation 2000; 102(18): 2269–2275.

30. Taube A, Schlich R, Sell H et al. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 302(11): H2148-H2165.

31. Jelic S, Lederer DJ, Adams T et al. Vascular inflammation in obesity and sleep apnea. Circulation 2010; 121(8): 1014–1021.

32. Apovian CM, Gokce N. Obesity and cardiovascular disease. Circulation 2012; 125(9): 1178–1182.

33. Schulz E, Jansen T, Wenzel P et al. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10(6): 1115–1126.

34. Paulus WJ, Tschoepe C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2013; 62(4): 263–271.

35. Van Heerebeek L, Hamdani N, Falcao-Pires I et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012; 126(7): 830–839.

36. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance and rhythmicity. Physiol Rev 2003; 83(1): 59–115.

37. Kalogeropoulos A, Georgiopoulou V, Psaty BM et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010; 55(19): 2129–2137.

38. Shah KB, Kop WJ, Christenson RH et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011; 57(6): 874–882.

39. Matsubara J, Sugiyama S, Nozaki T et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011; 57(7): 861–869.

40. Kasner M, Westermann D, Lopez B et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 2011; 57(8): 977–985.

41. Mohammed SF, Ohtani T, Korinek J et al. Mineralocorticoid Accelerates Transition to Heart Failure with Preserved Ejection Fraction Via „Non-genomic Effects“. Circulation 2010; 122(4): 370–378.

42. Hummel SL, Seymour EM, Brook RD et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 2012; 60(5): 1200–1206.

43. Tian N, Moore RS, Braddy S et al. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 293(6): H3388-H3395.

44. Macdougall IC, Canaud B, de Francisco AL et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 2012; 14(8): 882–886.

45. Shenouda SM, Widlansky ME, Chen K et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011; 124(4): 444–453.

46. Rajapakse AG, Yepuri G, Carvas JM et al. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. PLoS One 2011; 6(4): e19237.

47. Kamimura D, Ohtani T, Sakata Y et al. Ca2+ Reentry Mode of Na+/Ca2+ Exchanger As a New Therapeutic Target for Heart Failure With Preserved Ejection Fraction. Eur Heart J 2012; 33(11): 1408–1416.

48. Cioffi G, Senni M, Tarantini L et al. Analysis of Circumferencial and Longitudinal Left Ventricular Systolic Function in Patients with Non-Ischemic Chronic Heart Failure and Preserved Ejection Fraction (from the CARRY-IN HFpEF Study). Am J Cardiol 2012; 109(3): 383–389.

49. Patel DA, Lavie CJ, Milani RV et al. Association of Left Ventricular Geometry With Left Atrial Enlargement in Patient with Preserved Ejection Fraction. Congest Heart Fail 2011. Dostupné z DOI: <http://doi: 10.1111/j.1751–7133.2011.00264.x>.

50. Aizawa Y, Sakata Y, Mano T et al. Transition From Asymptomatic Diastolic Dysfunction to Heart Failure With Preserved Ejection Fraction. Circ J 2011; 75(3): 596–602.

51. McMurray JJM, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787–1847.

52. Hradec, J. Vítovec, J. Špinar, Summary of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Prepared by the Czech Society of Cardiology, Cor et Vasa 55 (2013) e25–e40. Dostupné z DOI: <http://doi:10.1016/j.crvasa.2013.01.002>.

53. Borlaug BA, Nishimuta PS, Lam CSP et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3(5): 588–595.

54. Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995; 96(3): 1280–1287.

55. Yamamoto K, Burnett jr. JC, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28(6): 988–994.

56. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40(5): 976–982.

57. Tsutamoto T, Wada A, Sakai H et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47(3): 582–586.

58. Knudsen CW, Omland T, Clopton P et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: An analysis from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2005; 46(5): 838–844.

59. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109(5): 594–600.

60. Daneshvar D, Wei J, Tolstrup K et al. Diastolic Dysfunction: Improved Understanding Using Emerging Imaging Techniques. Am Heart J 2010; 160(3): 394–404.

61. Kremastinos DT, Hamodraka E, Parissis J et al. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalasemia major. Am Heart J 2010; 159(1): 68–74.

62. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009; 53(11): 905–918.

63. Badheka AO, Rathod A, Kizilbash MA et al. Comparison of Mortality and Morbidity in Patients with Atrial Fibrillation and Heart Failure with Preserved Versus Decreased Left Ventricular Ejection Fraction. Am J Cardiol 2011; 108(9): 1283–1288.

64. Leung CC, Moondra V, Catherwood E et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106(2): 284–286.

65. Kappor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved ejection systolic function: a U-shaped relationship. Am Heart J 2010; 159(1): 75–80.

66. Edelmann F, Stahrenberg R, Polzin F et al. impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters: quality of life in diastolic dysfunction. Am Heart J 2011; 161(4): 797–804.

67. Parissis JT, Ikonomidis I, Rafouli-Stergiou P et al. Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. Am J Cardiol 2011; 107(1): 79–84.

68. Rusinaru D, Buiciuc O, Leborgne L et al. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2009; 103(3): 405–410.

69. Park HE, Kim J, Kim H. Ventricular dyssynchrony of idiopathic versus pacing-induced left bundle branch block and its prognostic effect in patients with preserved left ventricular systolic function. Am J Cardiol 2012; 109(4): 556–562.

70. Vítovec J, Špinarová L, Špinar J Léčba chronického srdečního selhání v interní ambulanci. Vnitř Lék 2009; 55(Suppl 1): 9–12.

71. Bhuiyan T, Maurer MS Heart Failure With Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risc Rep 2011; 5(5): 440–449.

72. Desai AS, Lewis EF, Li R et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162(6): 966–972.

73. Špinar J, Vítovec J. Zasnouben se špičkovou kočkou aneb ENGAGEd to TOPCAT. Kardiol Rev 2013; 15(4): 252–253.

74. Daniel KE, Wells G, Stewart K et al. Effect of aldosterone antagonism on exercise tolerance, doppler diastolic function, and quality of life in older woman with diastolic heart failure. Congest Heart Fail 2009; 15(2): 68–74.

75. Parthasarathy HK, Pieske B, Weisskopf M et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 2009; 11(10): 980–989.

76. Tehrani F, Phan A, Chien CHV et al. Value of medical therapy in patients older than 80 years of age with heart failure and preserved ejection fraction. Am J Cardiol 2009; 103(6): 829–833.

77. Miller AB, Pina IL. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook. Congest Heart Failure 2009; 15(4): 186–192.

78. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777–781.

79. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338–2345.

80. Paulus WJ, van Ballegoij JJM. Treatment of heart failure with normal ejection fraction. An inconvenient truth! J Am Coll Cardiol 2010; 55(6): 526–537.

81. Farasat SM, Bolger DT, Shetty V et al. Effect of Beta-Blocker Therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 2010; 105(2): 229–234.

82. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215–225.

83. Zakir RM, Al-Dehneh A, Maher J et al. Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. Congest Heart Fail 2007; 13(3): 164–169.

84. Cohen RS, Karlin P, Yushak M et al. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older adult patients with anemia and heart failure with a preserved ejection fraction. Congest Heart Fail 2010; 16(3): 96–103.

85. Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11(2): 214–222.

86. Guazzi M, Vicenzi M, Arena R et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4(1): 8–17.

87. Guazzi M, Vicenzi M, Arena R et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124(2): 164–174.

88. Antoniades C, Bakogiannis C, Leeson P et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124(3): 335–345.

89. Westermann D, Riad A, Richter U et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol 2009; 104(5): 499–509.

90. Heusch G. Diastolic heart failure: a misNOmer. Basic Res Cardiol 2009; 104: 465–467.

91. Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Prospective comparison of ARNI with ARB on Management Of heart FailUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. Lancet 2012; 380(9851): 1387–1395.

92. Vítovec J, Špinarová L, Špinar J. Nové možnosti léčby srdečního selhání a hypertenze. Kardiol Rev Int Med 2013, 15(2): 113–117.

93. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult – Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46(6): 1116–1143.

94. Borlaug BA, Jaber WA, Ommen SR et al. Diastolic Relaxation and Compliance Reserve during Dynamic Exercise in Heart Failure With Preserved Ejection Fraction. Heart 2011; 97(12): 964–969.

95. Kitzman DW, Brubaker PH, Morgan TM et al. Exercise Training in Older Patients with Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial. Circ Heart Fail 2010; 3(6): 659–667.